✦ LIBER ✦

Expression of Ki-1 antigen (CD30) in mesenchymal tumors

✍ Scribed by Gunhild Mechtersheimer; Peter Möller

Publisher: John Wiley and Sons
Year: 1990
Tongue: English
Weight: 815 KB
Volume: 66
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19901015)66:8<1732::aid-cncr2820660815>3.0.co;2-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Ki-1 (CD30) antigen is released by Ki-1-

Ki-1 (CD30) antigen is released by Ki-1-positive tumor cells in vitro and in vivo. I. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay

✍ Olivera Josimovic-Alasevic; Horst Dürkop; Roland Schwarting; Eva Backé; Harald S 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 626 KB

Ki-1 (CD30) antigen is released by Ki-l-positive tumor cells in vitro and in vivo I. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay\* An enzyme-linked immunosorbent assay (ELISA) has been

Expression of the CD30 antigen in non-ly

Expression of the CD30 antigen in non-lymphoid tissues and cells

✍ D�rkop, Horst; Foss, Hans-Dieter; Eitelbach, Florian; Anagnostopoulos, Ioannis; 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 196 KB 👁 2 views

Originally, expression of the CD30 antigen was shown to be typical of the tumour cells of Hodgkin's disease (HD) and of anaplastic large cell lymphomas (ALCLs). In reactive lymphoid tissue, CD30 is expressed only in a small population of activated lymphoid blasts. Since then, several reports have be

Expression of the tumor-rejection antige

Expression of the tumor-rejection antigen SART1 in brain tumors

✍ Toshihiro Imaizumi; Terukazu Kuramoto; Kazuko Matsunaga; Shigeki Shichijo; Shige 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 French ⚖ 156 KB 👁 2 views

We have reported a tumor-rejection antigen, SART1 259 , possessing tumor epitopes capable of inducing cytotoxic T lymphocytes (CTLs) in epithelial-cancer patients. This study investigated the expression of SART1 259 antigen in brain tumors, to explore for a potential molecule for use in specific imm

Clinical relevance of Ki-67 expression i

Clinical relevance of Ki-67 expression in bone tumors

✍ Katia Scotlandi; Massimo Serra; M. Cristina Manara; Daniela Maurici; Stefania Be 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 1015 KB

Expression of the SART-1 tumor rejection

Expression of the SART-1 tumor rejection antigen in breast cancer

✍ Mayumi Kawamoto; Shigeki Shichijo; Yasuhisa Imai; Toshihiko Imaizumi; Toshihiro 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 French ⚖ 127 KB 👁 2 views

We investigated in breast cancers the expression of the SART-1 gene encoding tumor rejection antigens. SART-1 mRNA was expressed in all of the samples tested. The SART-1 800 antigen was detectable in 20 of 50 (40%) breast cancer tissues and all breast cancer cell lines tested, but not in normal brea

Activation of the Ki-ras gene in spontan

Activation of the Ki-ras gene in spontaneous and chemically induced lung tumors in CD-1 mice

✍ Sujata Manam; Richard D. Storer; Srinivasa Prahalada; Karen R. Leander; Andrew R 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 712 KB

## Abstract As part of an evaluation of the effectiveness of using __ras__ mutation analysis for distinguishing carcinogen‐induced from spontaneous tumors, we examined the profile of __ras__ gene point mutations in spontaneous, 7,12‐dimethylbenz[__a__]anthracene (DMBA)‐induced, and N‐nitrosodiethyl